A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth

被引:0
|
作者
A Rasola
M Fassetta
F De Bacco
L D'Alessandro
D Gramaglia
M F Di Renzo
P M Comoglio
机构
[1] Università degli Studi di Padova,Department of Biomedical Sciences
[2] University of Torino Medical School,Division of Molecular Oncology
[3] Laboratory of Cancer Genetics,undefined
[4] Institute for Cancer Research and Treatment (IRCC),undefined
[5] University of Torino Medical School,undefined
来源
Oncogene | 2007年 / 26卷
关键词
apoptosis; -catenin; colorectal carcinoma; hepatocyte growth factor; invasive growth;
D O I
暂无
中图分类号
学科分类号
摘要
Overexpressed or activated hepatocyte growth factor receptor, encoded by the MET proto-oncogene, was found in the majority of colorectal carcinomas (CRCs), whose stepwise progression to malignancy requires transcriptional activation of β-catenin. We here demonstrate that a functional crosstalk between Met and β-catenin signaling sustains and increases CRC cell invasive properties. Hepatocyte growth factor (HGF) stimulation prompts β-catenin tyrosine phosphorylation and dissociation from Met, and upregulates β-catenin expression via the phosphatidylinositol 3-kinase pathway in conditions that mimic those found by the invading and metastasizing cells. Additionally, a transcriptionally active form of β-catenin, known to be oncogenic, enhances Met expression. Furthermore, HGF treatment increases the activity of the β-catenin-regulated T-cell factor transcription factor in cells expressing the wild-type or the oncogenic β-catenin. In the mirror experiments, either Met or β-catenin knocking down also reduces their protein level. In biological assays, β-catenin knocking down abrogates the HGF-induced motile phenotype, whereas active β-catenin fosters ligand-independent cell scattering. Met and β-catenin also cooperate in promoting entry into the cell cycle and in protecting cells from apoptosis. In conclusion, Met and β-catenin pathways are mutually activated in CRC cells. This might generate a self-amplifying positive feedback loop resulting in the upregulation of the invasive growth properties of CRC cells.
引用
收藏
页码:1078 / 1087
页数:9
相关论文
共 50 条
  • [21] Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor
    Spix, Julie K.
    Chay, Edward Y.
    Block, Ethan R.
    Klarlund, Jes K.
    EXPERIMENTAL CELL RESEARCH, 2007, 313 (15) : 3319 - 3325
  • [22] Effects of hepatocyte growth factor/scatter factor on the invasion of colorectal cancer cells in vitro
    Li, Hong-Wu
    Shan, Ji-Xian
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (25) : 3877 - 3881
  • [24] A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer
    Ou, Baochi
    Cheng, Xi
    Xu, Zhuoqing
    Chen, Chun
    Shen, Xiaohui
    Zhao, Jingkun
    Lu, Aiguo
    CELL DEATH & DISEASE, 2019, 10 (9)
  • [25] A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer
    Baochi Ou
    Xi Cheng
    Zhuoqing Xu
    Chun Chen
    Xiaohui Shen
    Jingkun Zhao
    Aiguo Lu
    Cell Death & Disease, 10
  • [26] Hepatocyte growth factor scatter factor disrupts epithelial tumour cell-cell adhesion:: Involvement of β-catenin
    Hiscox, S
    Jiang, WG
    ANTICANCER RESEARCH, 1999, 19 (1A) : 509 - 517
  • [27] The hepatocyte growth factor receptor, Met, in prostate cancer invasion and metastasis
    Knudsen, BS
    You, X
    Gmyrek, G
    Vaughan, ED
    Vande Woude, G
    LABORATORY INVESTIGATION, 2002, 82 (01) : 167A - 168A
  • [28] The hepatocyte growth factor receptor, Met, in prostate cancer invasion and metastasis
    Knudsen, BS
    You, X
    Gmyrek, G
    Vaughan, ED
    Vande Woude, G
    MODERN PATHOLOGY, 2002, 15 (01) : 167A - 168A
  • [29] Hepatocyte growth factor receptor (HGFR) as a potential lung cancer target
    Ahmed, Haidar
    Skouta, Rachid
    FASEB JOURNAL, 2018, 32 (01):
  • [30] Hepatocyte growth factor, its receptor, and their potential value in cancer therapies
    Jiang, WG
    Martin, TA
    Parr, C
    Davies, G
    Matsumoto, K
    Nakamura, T
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 53 (01) : 35 - 69